LEPU BIO-B(02157),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02157 LEPU BIO-B

Market Closed 04-17 16:08:14

6.370

-0.140

-2.15%

High6.650	Low6.180	Vol17.03M
Open6.560	D1 Closing6.510	Amplitude7.22%
Mkt Cap11.49B	Tradable Cap11.49B	Total Shares1.80B
T/O108.01M	T/O Rate0.94%	Tradable Shares1.80B
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"02157","market":"HK","secType":"STK","nameCN":"LEPU BIO-B","latestPrice":6.37,"timestamp":1776413294004,"preClose":6.51,"halted":0,"volume":17034000,"delay":0,"changeRate":-0.021505376344085975,"floatShares":1804000000,"shares":1804000000,"eps":0.1713363659595817,"marketStatus":"Market Closed","change":-0.14,"latestTime":"04-17 16:08:14","open":6.56,"high":6.65,"low":6.18,"amount":108008721,"amplitude":0.072197,"askPrice":6.37,"askSize":315000,"bidPrice":6.35,"bidSize":3000,"shortable":3,"etf":0,"ttmEps":0.1713363659595817,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1776648600000},"marketStatusCode":7,"adr":0,"listingDate":1645545600000,"exchange":"SEHK","adjPreClose":6.51,"openAndCloseTimeList":[[1776389400000,1776398400000],[1776402000000,1776412800000]],"volumeRatio":1.093948550716093,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02157","defaultTab":"news","newsList":[{"id":"2625935640","title":"Assessing Lepu Biopharma’s Valuation After Earnings Turnaround And Share Price Surge","url":"https://stock-news.laohu8.com/highlight/detail?id=2625935640","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625935640?lang=en_us&edition=fundamental","pubTime":"2026-04-06 01:16","pubTimestamp":1775409405,"startTime":"0","endTime":"0","summary":"Earnings turnaround puts Lepu Biopharma back on investors’ radar\nLepu Biopharma (SEHK:2157) has drawn fresh attention after reporting full year 2025 results that shifted from a net loss to net income of CNY 261.36 million, with sales of CNY 934.87 million.\nThe company also moved from a basic loss per share of CNY 0.24 to basic earnings per share of CNY 0.15 from continuing operations, a change that gives investors new financial data points to assess the stock.\nSee our latest analysis for Lepu...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2157/lepu-biopharma-shares/news/assessing-lepu-biopharmas-valuation-after-earnings-turnaroun","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2157/lepu-biopharma-shares/news/assessing-lepu-biopharmas-valuation-after-earnings-turnaroun","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["02157","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174315525","title":"LEPU BIO-B Posts March 2026 Monthly Return: 1.80 Bln Shares Outstanding, No Capital Changes","url":"https://stock-news.laohu8.com/highlight/detail?id=1174315525","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174315525?lang=en_us&edition=fundamental","pubTime":"2026-04-02 17:25","pubTimestamp":1775121908,"startTime":"0","endTime":"0","summary":"Lepu Biopharma Co., Ltd. filed its monthly return for the period ended 31 March 2026, confirming a stable capital structure and full compliance with Hong Kong Stock Exchange public float...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622800406","title":"Assessing Lepu Biopharma (SEHK:2157) Valuation After Its Earnings Turnaround And Recent Share Price Strength","url":"https://stock-news.laohu8.com/highlight/detail?id=2622800406","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622800406?lang=en_us&edition=fundamental","pubTime":"2026-03-28 12:21","pubTimestamp":1774671667,"startTime":"0","endTime":"0","summary":"Lepu Biopharma (SEHK:2157) just reported full year 2025 earnings, with sales of CN¥934.87 million and net income of CN¥261.36 million, compared with a net loss a year earlier.\nSee our latest analysis for Lepu Biopharma.\nThe earnings swing appears to be feeding into sentiment, with the HK$5.6 share price sitting after an 8.74% 1 day share price return, a 22.81% 30 day share price return and a 46.98% 1 year total shareholder return. This suggests that momentum has been building recently.\nIf...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2157/lepu-biopharma-shares/news/assessing-lepu-biopharma-sehk2157-valuation-after-its-earnin","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2157/lepu-biopharma-shares/news/assessing-lepu-biopharma-sehk2157-valuation-after-its-earnin","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","02157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149528263","title":"HK Pharma Stocks Gained. CSPC Pharma Up 13%; Lepu Bio Up 7%; Hengrui Pharma And Junshi Bio Up 6%; HBM, Beigene, Sihuan Pharm Up 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1149528263","media":"Tiger Newspress","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1149528263?lang=en_us&edition=fundamental","pubTime":"2026-03-27 14:14","pubTimestamp":1774592089,"startTime":"0","endTime":"0","summary":"HK Pharma Stocks Gained. CSPC Pharma Up 13%; Lepu Bio up 7%; Hengrui Pharma and Junshi Bio Up 6%; HBM, Beigene, $Sihuan Pharm(00460)$ Up 5%.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"69cd48097efa50f044ce5ac6380125f5","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06606","09688","09606","09995","09966","02268","02157","01276","02137","02359","03759","06978","03347","01093","02269","01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622868011","title":"Lepu Biopharma (SEHK:2157) Profit Swing To C¥41.7m Tests Bearish Earnings Narratives","url":"https://stock-news.laohu8.com/highlight/detail?id=2622868011","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622868011?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:15","pubTimestamp":1774523714,"startTime":"0","endTime":"0","summary":"Lepu Biopharma (SEHK:2157) has just posted its FY 2025 numbers with first half revenue of C¥465.9 million and basic EPS of C¥0.024, while the trailing twelve months show revenue of C¥934.9 million and basic EPS of C¥0.15. Over the last few reporting halves, revenue has moved from C¥133.3 million in 1H 2024 to C¥234.5 million in 2H 2024 and then to C¥465.9 million in 1H 2025. Net income has shifted from losses of C¥192.4 million and C¥218.9 million to a profit of C¥41.7 million, pointing to a...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2157/lepu-biopharma-shares/news/lepu-biopharma-sehk2157-profit-swing-to-c417m-tests-bearish","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2157/lepu-biopharma-shares/news/lepu-biopharma-sehk2157-profit-swing-to-c417m-tests-bearish","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","02157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185473329","title":"Stock Track | LEPU BIO-B Soars 14.84% Intraday on Strong Annual Results Showing Revenue Surge and Profit Turnaround","url":"https://stock-news.laohu8.com/highlight/detail?id=1185473329","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1185473329?lang=en_us&edition=fundamental","pubTime":"2026-03-26 11:12","pubTimestamp":1774494758,"startTime":"0","endTime":"0","summary":"LEPU BIO-B's stock price soared 14.84% during the intraday session on Thursday, breaking above its half-year moving average.The significant surge followed the release of the company's annual report,...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"b776b6268e0a69a5ca2da5ea0fb0b0d4","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199006540","title":"Robust Earnings Fuel Continued Gains for Hong Kong Stock Connect Biotech ETFs Amid Market Downturn","url":"https://stock-news.laohu8.com/highlight/detail?id=1199006540","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199006540?lang=en_us&edition=fundamental","pubTime":"2026-03-26 11:11","pubTimestamp":1774494703,"startTime":"0","endTime":"0","summary":"On March 26, Hong Kong Stock Connect pharmaceutical stocks demonstrated resilience against the broader market trend. The Huabao Hong Kong Stock Connect Innovative Drug ETF (520880), which focuses...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["520880","BK1574","BK4588","BK1161","06978","BK4585","VXUS","02157","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148472362","title":"HK Pharma Stocks Gained. XuanzhuBio Up 9%; Xtalpi, Lepu Bio And Ascletis Up 6%; Akeso Up 5%; Skb Bio Up 4%.","url":"https://stock-news.laohu8.com/highlight/detail?id=1148472362","media":"Tiger Newspress","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148472362?lang=en_us&edition=fundamental","pubTime":"2026-03-26 09:54","pubTimestamp":1774490045,"startTime":"0","endTime":"0","summary":"HK Pharma Stocks Gained. XuanzhuBio up 9%; Xtalpi, Lepu Bio and Ascletis up 6%; Akeso up 5%; Skb Bio up 4%. ","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"b776b6268e0a69a5ca2da5ea0fb0b0d4","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966","02268","01672","02137","02359","03759","06978","09606","03347","02575","02228","02157","09995","02269","06606","09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181020269","title":"LEPU BIO-B Reports Annual Profit Turnaround with Key Drug Candidates Advancing","url":"https://stock-news.laohu8.com/highlight/detail?id=1181020269","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181020269?lang=en_us&edition=fundamental","pubTime":"2026-03-25 16:45","pubTimestamp":1774428303,"startTime":"0","endTime":"0","summary":"LEPU BIO-B (02157) announced its annual results for the period ending December 31, 2025. The group recorded revenue of 935 million Chinese yuan, representing an increase of 154.19% compared to the...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622469025","title":"Lepu Biopharma FY2025 profit attributable to owners climbs to RMB261 million; revenue rises to RMB935 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622469025","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622469025?lang=en_us&edition=fundamental","pubTime":"2026-03-25 16:33","pubTimestamp":1774427606,"startTime":"0","endTime":"0","summary":"FY2025 profit attributable to owners climbed to RMB261 million, swinging from a loss a year earlier, while earnings per share rose to RMB0.15.FY2025 operating income improved to RMB285 million, reversing from an operating loss a year earlier, on higher revenue and other gains.FY2025 revenue more than doubled to RMB935 million, including RMB501 million from domestic commercialization and RMB424 million from licensing activities.FY2025 selling and marketing expenses jumped 64.6% to RMB240 million on higher domestic commercialization.FY2025 research and development expenses fell 8.5% to RMB401 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lepu Biopharma Co. Ltd. published the original content used to generate this news brief via","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDLPC1TX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622025117","title":"Lepu Biopharma FY2025; EGFR-targeting ADC Meyiuheng gains China approval for R/M NPC; revenue jumps to CNY 935 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622025117","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622025117?lang=en_us&edition=fundamental","pubTime":"2026-03-25 16:32","pubTimestamp":1774427546,"startTime":"0","endTime":"0","summary":"The company framed the launch as a first-in-class approval in China, which could support earlier uptake and differentiation as it expands indications and combination regimens.FY2025 revenue rose to CNY 935 million, while FY2025 profit attributable to owners climbed to CNY 261 million.FY2025 sales of commercialized products increased 66.8% to CNY 501 million, and FY2025 licensing revenue jumped to CNY 424 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lepu Biopharma Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 25, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDL1tlzTT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622973025","title":"Lepu Biopharma Co Ltd -  Profit Attributable RMB261.4 Mln for Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2622973025","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622973025?lang=en_us&edition=fundamental","pubTime":"2026-03-25 16:30","pubTimestamp":1774427456,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nPLXBD96BF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619919488","title":"Assessing Lepu Biopharma (SEHK:2157) Valuation After New 2025 Profit Guidance And Dividend Discussion","url":"https://stock-news.laohu8.com/highlight/detail?id=2619919488","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619919488?lang=en_us&edition=fundamental","pubTime":"2026-03-15 23:19","pubTimestamp":1773587973,"startTime":"0","endTime":"0","summary":"Why Lepu Biopharma’s Latest Guidance Matters\nLepu Biopharma (SEHK:2157) has drawn fresh attention after issuing earnings guidance that points to at least RMB 200 million in net profit for 2025, compared with a RMB 411 million loss in 2024.\nThe company links this projected swing to revenue from PUYOUHENG and newly approved MEIYOUHENG, expanded licensing income, and a one off reclassification gain on an investment, while an upcoming March 25 board meeting will review the full 2025 results and...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2157/lepu-biopharma-shares/news/assessing-lepu-biopharma-sehk2157-valuation-after-new-2025-p","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2157/lepu-biopharma-shares/news/assessing-lepu-biopharma-sehk2157-valuation-after-new-2025-p","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","02157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161759806","title":"LEPU BIO-B (02157) Sets 25 March 2026 Board Meeting to Review FY 2025 Results and Final-Dividend Proposal","url":"https://stock-news.laohu8.com/highlight/detail?id=1161759806","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161759806?lang=en_us&edition=fundamental","pubTime":"2026-03-11 21:03","pubTimestamp":1773234193,"startTime":"0","endTime":"0","summary":"LEPU BIOPHARMA CO., LTD. (LEPU BIO-B, 02157) has scheduled a board meeting for 25 March 2026. Directors will examine and approve the consolidated financial statements for the year ended 31 December...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618518999","title":"Lepu Biopharma Says AstraZeneca Begins Phase 3 Trial of CMG901 Cancer Therapy; Shares Jump 7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618518999","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618518999?lang=en_us&edition=fundamental","pubTime":"2026-03-11 10:08","pubTimestamp":1773194916,"startTime":"0","endTime":"0","summary":"Lepu Biopharma Co  said AstraZeneca has initiated a Phase 3 clinical study of its antibody-drug conjugate candidate CMG901, triggering a milestone payment of $45 million under their collaboration agreement, according to a Wednesday Hong Kong bourse filing.The trial is evaluating sonesitatug vedotin  in combination with capecitabine, with or without rilvegostomig, for first-line treatment of Claudin 18.2-positive, HER2-negative advanced or metastatic gastric and related cancers.CMG901 was developed through KYM Biosciences, a joint venture between Lepu Biopharma and Keymed Biosciences .Lepu Biopharma's shares jumped nearly 7% in early-morning trade on Wednesday.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1587","BK1574","02157","BK1583","02162","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180096118","title":"AstraZeneca Pays $45 Million Milestone Fee to LEPU BIO-B","url":"https://stock-news.laohu8.com/highlight/detail?id=1180096118","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180096118?lang=en_us&edition=fundamental","pubTime":"2026-03-11 06:54","pubTimestamp":1773183257,"startTime":"0","endTime":"0","summary":"LEPU BIO-B (02157) has announced that in February 2023, KYM Biosciences Inc. and AstraZeneca entered into a global exclusive licensing agreement to develop and commercialize CMG901, also known as...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02157","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137216932","title":"LEPU BIO-B Issues Positive Profit Alert, Anticipates Net Profit Attributable to Owners of No Less Than RMB 200 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1137216932","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137216932?lang=en_us&edition=fundamental","pubTime":"2026-03-11 06:26","pubTimestamp":1773181581,"startTime":"0","endTime":"0","summary":"LEPU BIO-B (02157) has announced a profit alert. The company expects its net profit attributable to shareholders for the fiscal year ending December 31, 2025, to be no less than RMB 200 million. This...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02157","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618962373","title":"Lepu Biopharma forecasts FY2025 net profit attributable to shareholders of at least RMB200 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2618962373","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618962373?lang=en_us&edition=fundamental","pubTime":"2026-03-11 06:09","pubTimestamp":1773180585,"startTime":"0","endTime":"0","summary":"Lepu Biopharma expects net profit attributable to shareholders for FY2025 to be at least RMB200 million, compared with a net loss of about RMB411 million in FY2024. The company cited revenue growth from domestic commercialization and licensing, including higher revenue from PUYOUHENG and revenue from MEIYOUHENG after its NMPA approval in October 2025. It also cited a one-off, non-operating gain from reclassifying an investment from associate to fair value after it no longer had significant influence over the investee.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lepu Biopharma Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nNDLc93zCG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618962599","title":"Lepu Biopharma Co  - Expected Result Due to Revenue Increase From Puyouheng and Meiyouheng After Nmpa Approval in October 2025, Others in FY","url":"https://stock-news.laohu8.com/highlight/detail?id=2618962599","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618962599?lang=en_us&edition=fundamental","pubTime":"2026-03-11 06:09","pubTimestamp":1773180570,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nFWN3ZY1OH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02157","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618962585","title":"Lepu Biopharma - Expects FY Net Profit Attributable of at Least RMB200 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2618962585","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618962585?lang=en_us&edition=fundamental","pubTime":"2026-03-11 06:09","pubTimestamp":1773180570,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nFWN3ZY1OH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02157","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.lepubiopharma.com","stockEarnings":[{"period":"1week","weight":0.1021},{"period":"1month","weight":0.2064},{"period":"3month","weight":0.1498},{"period":"6month","weight":-0.0155},{"period":"1year","weight":0.6086},{"period":"ytd","weight":0.2817}],"compareEarnings":[{"period":"1week","weight":0.0103},{"period":"1month","weight":0.0052},{"period":"3month","weight":-0.0255},{"period":"6month","weight":0.0362},{"period":"1year","weight":0.2227},{"period":"ytd","weight":0.0207}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Lepu Biopharma Co Ltd is a company principally engaged in the sales of pharmaceutical products and the research and development of new drugs. The Company is focused on oncology therapeutics, in particular, targeted therapy and oncology immunotherapy. The Company is dedicated to developing innovative antibody-drug conjugate (ADC) through an ADC technology development platform. The Company’s clinical-stage drug candidates cover targeted therapeutics and an immunotherapeutic, including MRG003, MRG002, CMG901, MRG004A, CG0070, MRG006A, MRG007, and CTM012.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.070458},{"month":2,"riseRate":0.5,"avgChangeRate":0.087235},{"month":3,"riseRate":0.4,"avgChangeRate":-0.009016},{"month":4,"riseRate":1,"avgChangeRate":0.222056},{"month":5,"riseRate":0.5,"avgChangeRate":-0.007459},{"month":6,"riseRate":0.5,"avgChangeRate":-0.04556},{"month":7,"riseRate":0.5,"avgChangeRate":0.067498},{"month":8,"riseRate":0.5,"avgChangeRate":-0.002458},{"month":9,"riseRate":0.5,"avgChangeRate":0.085192},{"month":10,"riseRate":0.25,"avgChangeRate":-0.14162},{"month":11,"riseRate":0.25,"avgChangeRate":0.007333},{"month":12,"riseRate":0.25,"avgChangeRate":-0.05091}],"exchange":"SEHK","name":"LEPU BIO-B","nameEN":"LEPU BIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"LEPU BIO-B(02157),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest LEPU BIO-B(02157) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"LEPU BIO-B,02157,LEPU BIO-B股票,LEPU BIO-B股票老虎,LEPU BIO-B股票老虎国际,LEPU BIO-B行情,LEPU BIO-B股票行情,LEPU BIO-B股价,LEPU BIO-B股市,LEPU BIO-B股票价格,LEPU BIO-B股票交易,LEPU BIO-B股票购买,LEPU BIO-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"LEPU BIO-B(02157),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest LEPU BIO-B(02157) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}